[go: up one dir, main page]

MA31666B1 - Cyclic peptide cxcr4 antagonists - Google Patents

Cyclic peptide cxcr4 antagonists

Info

Publication number
MA31666B1
MA31666B1 MA32439A MA32439A MA31666B1 MA 31666 B1 MA31666 B1 MA 31666B1 MA 32439 A MA32439 A MA 32439A MA 32439 A MA32439 A MA 32439A MA 31666 B1 MA31666 B1 MA 31666B1
Authority
MA
Morocco
Prior art keywords
cxcr4 peptide
periodic anti
periodic
cxcr4
peptide
Prior art date
Application number
MA32439A
Other languages
Arabic (ar)
English (en)
Inventor
Wayne David Kohn
Sheng-Bin Peng
Liang Zeng Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31666(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA31666B1 publication Critical patent/MA31666B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des antagonistes cxcr4 de peptides cyclisés par lactame, utiles dans le traitement des cancers, de la polyarthrite rhumatoïde, de la fibrose pulmonaire et de l'infection au vih.
MA32439A 2007-05-30 2009-12-21 Cyclic peptide cxcr4 antagonists MA31666B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94080207P 2007-05-30 2007-05-30
US94099607P 2007-05-31 2007-05-31
PCT/US2008/064177 WO2008150689A1 (fr) 2007-05-30 2008-05-20 Antagonistes cxcr4 de peptides cycliques

Publications (1)

Publication Number Publication Date
MA31666B1 true MA31666B1 (fr) 2010-09-01

Family

ID=39831600

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32439A MA31666B1 (fr) 2007-05-30 2009-12-21 Cyclic peptide cxcr4 antagonists

Country Status (32)

Country Link
US (3) US7691813B2 (fr)
EP (2) EP2377579A1 (fr)
JP (1) JP5358564B2 (fr)
KR (2) KR101319740B1 (fr)
CN (1) CN101678213B (fr)
AR (1) AR066648A1 (fr)
AT (1) ATE516853T1 (fr)
AU (1) AU2008260326B2 (fr)
BR (1) BRPI0812134A2 (fr)
CA (1) CA2688574C (fr)
CL (1) CL2008001467A1 (fr)
CO (1) CO6241137A2 (fr)
CR (1) CR11105A (fr)
CY (1) CY1111815T1 (fr)
DK (1) DK2160221T3 (fr)
DO (1) DOP2009000270A (fr)
EA (1) EA017716B1 (fr)
GT (1) GT200900304A (fr)
HR (1) HRP20110551T1 (fr)
IL (1) IL201685A (fr)
JO (1) JO2776B1 (fr)
MA (1) MA31666B1 (fr)
MX (1) MX2009012952A (fr)
MY (1) MY149432A (fr)
NZ (1) NZ580849A (fr)
PE (1) PE20090299A1 (fr)
PL (1) PL2160221T3 (fr)
PT (1) PT2160221E (fr)
TN (1) TN2009000496A1 (fr)
TW (1) TWI423987B (fr)
WO (1) WO2008150689A1 (fr)
ZA (1) ZA200908345B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2942798B1 (fr) * 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
IT1397901B1 (it) * 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
WO2012118124A1 (fr) * 2011-03-01 2012-09-07 国立大学法人京都大学 Nouvel antagoniste de récepteur de chimiokines
CA2838037C (fr) * 2011-06-07 2019-09-17 Polyphor Ag Peptidomimetiques en epingle a cheveux beta utilises comme antagonistes de cxc4
WO2013044500A1 (fr) * 2011-09-30 2013-04-04 Cheng Yun Applications d'un peptide immunogène du virus de l'hépatite c ou de ses dérivés pour la préparation prophylactique ou thérapeutique de l'arthrite
EP2771484A1 (fr) 2011-10-28 2014-09-03 Galderma Research & Development Nouveaux marqueurs d'infiltrat leucocytaire de rosacée et utilisations de ceux-ci
EP2979991A1 (fr) 2014-07-31 2016-02-03 Greif International Holding BV. Matériau multicouche, tapis de protection contre l'incendie avec ce matériau multicouche et ensemble de conteneur de transport et de stockage comprenant ledit tapis de protection contre l'incendie
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
WO2017176565A1 (fr) 2016-04-07 2017-10-12 Eli Lilly And Company Combinaisons d'un anticorps anti-b7-h1 et d'un agoniste du peptide cxcr4 pour le traitement d'une tumeur solide
CN109922818B (zh) * 2016-09-06 2024-02-20 主线生物科学公司 Cxcr4拮抗剂及使用方法
CN106841624B (zh) * 2017-01-26 2019-02-22 庄磊靓 抗人cd4和抗人cd184单克隆抗体作为标志物的应用
US11123437B2 (en) 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
KR20230145543A (ko) * 2017-09-05 2023-10-17 메인라인 바이오사이언스 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법
US11771736B2 (en) * 2017-12-21 2023-10-03 Mainline Biosciences (Shanghai) Co., Ltd. Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
WO2020053256A1 (fr) 2018-09-12 2020-03-19 Technische Universität München Agents thérapeutiques et diagnostiques dirigés contre le cxcr4 à sélectivité d'espèces réduite
US11639373B2 (en) 2018-09-12 2023-05-02 Technische Universität München Therapeutic and diagnostic agents for cancer
JP7541532B2 (ja) * 2019-04-18 2024-08-28 プロビンシャル・ヘルス・サービシーズ・オーソリティ 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物
EP4097120A4 (fr) * 2020-01-26 2024-05-01 Mainline Biosciences (Shanghai) Co., Ltd. Conjugué peptidique de liaison sélective à cxcr4 marqué par isotope et ses procédés de fabrication et d'utilisation
EP4232459A4 (fr) * 2020-10-21 2024-12-04 Provincial Health Services Authority Nouveaux composés ciblant cxcr4
US20240124517A1 (en) * 2020-12-25 2024-04-18 Chugai Seiyaku Kabushiki Kaisha Method for producing peptide compound containing n-substituted-amino acid residue
CN116615411A (zh) * 2020-12-25 2023-08-18 中外制药株式会社 包含n-取代氨基酸残基的肽化合物的制造方法
EP4043041A1 (fr) 2021-02-15 2022-08-17 Technische Universität München Cxcr4-ligands pour usage diagnostique et thérapeutique et leurs précurseurs
WO2023201435A1 (fr) * 2022-04-20 2023-10-26 Provincial Health Services Authority Composés ciblant cxcr4, et leurs procédés de fabrication et d'utilisation
CN115060901A (zh) * 2022-06-21 2022-09-16 中国医学科学院基础医学研究所 苹果酸酶2在制备矽肺病或肺纤维化相关疾病诊断试剂或治疗药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4391123B2 (ja) * 2002-10-24 2009-12-24 株式会社オーファンリンク 新規ｃｘｃｒ４アンタゴニスト
EP1991562A2 (fr) * 2006-02-27 2008-11-19 Technische Universität München Imagerie et traitement du cancer

Also Published As

Publication number Publication date
TN2009000496A1 (en) 2011-03-31
PE20090299A1 (es) 2009-03-19
TW200902556A (en) 2009-01-16
JP5358564B2 (ja) 2013-12-04
AU2008260326B2 (en) 2011-07-21
IL201685A (en) 2015-04-30
HRP20110551T1 (hr) 2011-09-30
CR11105A (es) 2010-04-12
JO2776B1 (en) 2014-03-15
US20080300177A1 (en) 2008-12-04
KR101169846B1 (ko) 2012-08-01
WO2008150689A1 (fr) 2008-12-11
BRPI0812134A2 (pt) 2014-11-18
DOP2009000270A (es) 2010-01-15
HK1141474A1 (en) 2010-11-12
CA2688574A1 (fr) 2008-12-11
MX2009012952A (es) 2009-12-11
IL201685A0 (en) 2010-05-31
CL2008001467A1 (es) 2008-12-05
EP2160221A1 (fr) 2010-03-10
AU2008260326A1 (en) 2008-12-11
CN101678213B (zh) 2013-11-06
ZA200908345B (en) 2011-02-23
MY149432A (en) 2013-08-30
TWI423987B (zh) 2014-01-21
USRE42274E1 (en) 2011-04-05
US7691813B2 (en) 2010-04-06
KR101319740B1 (ko) 2013-10-17
PL2160221T3 (pl) 2011-12-30
EA017716B1 (ru) 2013-02-28
CA2688574C (fr) 2014-02-18
EA200971129A1 (ru) 2010-04-30
US20100130409A1 (en) 2010-05-27
EP2160221B1 (fr) 2011-07-20
NZ580849A (en) 2012-03-30
PT2160221E (pt) 2011-09-12
JP2010529957A (ja) 2010-09-02
KR20100003737A (ko) 2010-01-11
DK2160221T3 (da) 2011-09-19
CY1111815T1 (el) 2015-10-07
ATE516853T1 (de) 2011-08-15
AR066648A1 (es) 2009-09-02
KR20110134519A (ko) 2011-12-14
CN101678213A (zh) 2010-03-24
CO6241137A2 (es) 2011-01-20
EP2377579A1 (fr) 2011-10-19
GT200900304A (es) 2011-11-09

Similar Documents

Publication Publication Date Title
MA31666B1 (fr) Cyclic peptide cxcr4 antagonists
NO20044039L (no) Konjugatorer av terapeutiske eller cytotoksiske midler og biologisk aktive peptider.
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
EA200802203A1 (ru) Дикетопиперазиновые и пиперидиновые производные в качестве противовирусных агентов
TR201909741T4 (tr) Kolon temizleme bileşimleri.
ATE419845T1 (de) Il-8-rezeptor-antagonisten
EP1667700A4 (fr) Compositions de peptides cycliques et methodes pour le traitement d'une dysfonction sexuelle
DE69938935D1 (de) Zyklische conotoxin-peptide
EA200600782A1 (ru) Терапевтические применения вариантов хемокинов
SE0302304D0 (sv) Novel compounds
EA200400399A1 (ru) Способы лечения легочных заболеваний
EA200500533A1 (ru) Пептидные производные - ингибиторы слияния при вич-инфекции
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
ATE386050T1 (de) Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden
WO2010057275A8 (fr) Peptides cycliques et leurs utilisations
FR2858234B1 (fr) Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers
MA27474A1 (fr) Vaccin
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
CY1106540T1 (el) Ετεροκυλικα υποκατεστημενες στη θεση 3 πιπεριδινο-2,6-διονες
ATE474046T1 (de) Vasopressin bindende l-nukleinsäure
DE602007006493D1 (de) Peptide mit proliferationshemmender wirkung
TH106960A (th) ไซคลิกเพพไทด์ cxcr4 แอนทาโกนิสต์
ATE468352T1 (de) Cyclische peptide, die als urotensin-ii- antagonisten wirken
PT1537210E (pt) Inibicao de oliconucleotidos decoy de expressao cd-40